Researchers at the University of Pittsburgh are examining the effectiveness of GLP-1 receptor agonists, commonly used for weight loss in medications like Ozempic and Wegovy, in treating obstructive sleep apnea—a condition affecting nearly 1 billion people globally. Their review of recent medical literature, published in JAMA Otolaryngology—Head and Neck Surgery on September 3, aims to assess whether these medications can benefit those suffering from this sleep disorder.
Read More
Obstructive sleep apnea is characterized by repeated breathing interruptions during sleep due to blocked airways. The condition is linked with cardiovascular disease, stroke, and increased mortality rates. The study highlights that obesity is present in 60 to 70 percent of obstructive sleep apnea patients, with a body mass index of 30 or higher identified as a primary modifiable risk factor. Consequently, addressing obesity through treatment could potentially alleviate sleep apnea symptoms.
Dr. Richard Schwab, a professor at the University of Pennsylvania, remarked that GLP-1 agonists could revolutionize sleep apnea treatment; however, he emphasized that these medications should be used alongside traditional treatments such as Continuous Positive Airway Pressure (CPAP) devices. Weight loss benefits may take several months to a year to noticeably impact sleep apnea severity.
The University of Pittsburgh researchers conducted an extensive literature search from January 2016 to November 2025, coinciding with the SCALE Sleep Apnea trial—the first randomized clinical trial that focused on GLP-1 receptor agonists for obstructive sleep apnea patients. The Wisconsin Sleep Cohort Study found that a 10 percent increase in body weight led to a 32 percent rise in the apnea-hypopnea index, a measure of sleep apnea severity. Their findings suggest that weight reduction is beneficial for improving this index.
Although current evidence indicates that GLP-1 receptor agonists could benefit some obstructive sleep apnea patients, the researchers noted that individuals without obesity are likely to see little improvement from weight loss strategies. Obesity narrows the airway, particularly around the pharynx, making it prone to collapse during sleep, as explained by the study's lead author, Dr. Alex Harris.
Excess body weight can lead to fat deposits in the throat and reduce lung capacity, exacerbating sleep apnea, especially when lying flat. Furthermore, obesity impacts hormonal functions, potentially causing leptin resistance—where the body does not properly respond to leptin, a hormone that regulates appetite and breathing drive.
The study suggests that GLP-1 receptor agonists could mitigate fat deposits contributing to sleep apnea, improve airway dynamics, and potentially stabilize normal breathing patterns. However, researchers cautioned that more studies are necessary to understand impacts on individuals with sleep apnea stemming from non-obesity factors.
Dr. Harris highlighted that GLP-1 receptor agonists are not substitutes for known sleep apnea treatments and emphasize the need for long-term medication adherence for effective management of both conditions. Recent findings also indicate that effective sleep apnea treatment may promote easier weight loss and better appetite regulation.